In Vitro and In Vivo Activity of Moxifloxacin against Community Respiratory Tract Pathogens

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.18, Iss.1, 1999-07, pp. : 57-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moxifloxacin in respiratory tract infections

By Miravitlles Marc

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 283-293

Informa Healthcare

Access to resources Recommend Favorite

Moxifloxacin: A Review of its Clinical Potential in the Management of Community-Acquired Respiratory Tract Infections

By Barman Balfour J.A. Lamb H.M.

Drugs, Vol. 59, Iss. 1, 2000-01 ,pp. : 115-139

Adis International

Access to resources Recommend Favorite

Respiratory tract infections: uncommon pathogens and misleading presentations

By Brill Simon E Lim Wei Shen Brown Jeremy S

Clinical Medicine, Vol. 11, Iss. 6, 2011-12 ,pp. : 567-570

Royal College Of Physicians

Access to resources Recommend Favorite

In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens

By Bowker K.E. Noel A.R. MacGowan A.P.

International Journal of Antimicrobial Agents, Vol. 22, Iss. 6, 2003-12 ,pp. : 557-561

Elsevier

Access to resources Recommend Favorite

Gatifloxacin in community-acquired respiratory tract infection

By Sethi Sanjay

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1847-1855

Informa Healthcare

Access to resources Recommend Favorite